Journal: Nature Communications

Article Title: Ligand-activated EGFR/MAPK signaling but not PI3K, are key resistance mechanisms to EGFR-therapy in colorectal cancer

doi: 10.1038/s41467-025-59588-3

Figure Lengend Snippet: a , b Scatterplot showing the relationship between gene-level alteration frequencies in ctDNA and archival tissues from ( a ) 141 patients who received prior anti-VEGF therapies, and ( b )113 patients who received prior anti-EGFR therapies. The effect size was estimated using Pearson’s correlation coefficient(r) calculated in GraphPad Prism, and the coefficient of determination (r 2 ), representing the proportion of variance explained by the relationship, is displayed on the scatter plot. c Comparison of percentage of patients with emerging alterations between patients with prior anti-EGFR therapies and those with prior anti-VEGF therapies. Alterations that were absent from tumor tissue samples but detected in plasma samples were defined as emerging alterations. (All genes with at least one emerging alteration listed). Only known and likely oncogenic alterations in each gene were considered for the analysis. P- value was calculated using a two-tailed Fisher’s exact test to compare the percentage of patients with emerging alterations between those who received anti-EGFR therapies and those who received anti-VEGF therapies. Source data are provided as a Source Data file.

Article Snippet: The effect size was estimated using Pearson’s correlation coefficient(r) calculated in GraphPad Prism, and the coefficient of determination (r 2 ), representing the proportion of variance explained by the relationship, is displayed on the scatter plot. c Comparison of percentage of patients with emerging alterations between patients with prior anti-EGFR therapies and those with prior anti-VEGF therapies.

Techniques: Comparison, Clinical Proteomics, Two Tailed Test